`
`
`
`
`
`
`
`
`
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`ETON PHARMACEUTICALS, INC.,
`Petitioner,
`
`v.
`
`EXELA PHARMA SCIENCES, LLC,
`Patent Owner.
`
`
`
`
`
`
`
`
`
`
`
`
`Case PGR2020-00064
`Patent 10,478,453
`
`
`
`
`
`
`
`
`
`
`
`
`PATENT OWNER EXELA PHARMA SCIENCES, LLC’S
`MANDATORY NOTICES
`
`
`
`Case PGR2020-00064
`Attorney Docket No: 48751-0005PS1
`
`
`
`
`
`PATENT OWNER’S MANDATORY NOTICES
`UNDER 37 C.F.R. § 42.8
`
`Pursuant to 37 C.F.R. § 42.8, Patent Owner, Exela Pharma Sciences, LLC
`
`(“Patent Owner”), hereby submits the following Mandatory Notices in response to
`
`the Petition for Post Grant Review of U.S. Patent No. 10,478,453 (the ’453
`
`patent).
`
`1.
`
`Real Party-In-Interest under 37 CFR § 42.8(b)(1)
`
`Exela Pharma Sciences, LLC is the Patent Owner and the Real Party-In-
`
`Interest in this proceeding.
`
`2.
`
`Related Matters under 37 CFR § 42.8(b)(2)
`
`A. The following judicial or administrative matters may affect or be
`affected by a decision in this proceeding:
`Exela Pharma Sciences, LLC v. Eton Pharms., Inc., Case No. 1:20-cv-
`
`00365-MN (D. Del., filed March 16, 2020); Exela Pharma Sciences LLC v. Avadel
`
`Legacy Pharms., LLC et al., No. 1:20-cv-00024-MN (D. Del., filed January 7,
`
`2020); Exela Pharma Sciences LLC v. Sandoz Inc., Case No. 1:20-cv-00645-MN
`
`(D. Del., filed May 14, 2020); and Exela Pharma Sciences LLC v. Sandoz Inc.,
`
`Case No. 1:20-cv-01393 (D. Colo., filed May 15, 2020).
`
`2
`
`
`
`B.
`
`Case PGR2020-00064
`Attorney Docket No: 48751-0005PS1
`The following issued U.S. patents and U.S. patent applications
`claim priority from the ’453 patent:
`U.S. Patents
`10,653,719
`
`10,583,155
`
`
`
`
`
`3.
`
`U.S. Applications
`16/746,028
`16/773,641
`16/850,726
`16/850,962
`16/850,973
`
`
`Lead and Back-Up Counsel, under 37 CFR § 42.8(b)(3)
`
`The Patent Owner designates the following lead and back-up counsel:
`
`LEAD COUNSEL
`Dorothy P. Whelan, Reg. No. 33,814
`3200 RBC Plaza
`60 South Sixth Street
`Minneapolis, MN 55402
`Tel:
`(612) 337-2509
`Email: PGR48751-0005PS1@fr.com
`Fax:
`(877) 769-7945
`
`4.
`
`BACK-UP COUNSEL
`Alana Mannige, Reg. No. 71,899
`3200 RBC Plaza
`60 South Sixth Street
`Minneapolis, MN 55402
`Tel:
`(404) 892-5005
`Email:
`PTABInbound@fr.com
`Fax:
`(877) 769-7945
`
`Service Information under 37 CFR § 42.8(b)(4)(i) et seq.
`
`Please address all correspondence and service to both counsel as listed
`
`above. Patent Owner consents to service by email at PGR48751-0005PS1@fr.com
`
`and PTABInbound@fr.com (ref.: Docket No. 48751-0005PS1).
`
`3
`
`
`
`Case PGR2020-00064
`Attorney Docket No: 48751-0005PS1
`Respectfully submitted,
`
`/Dorothy P. Whelan/
`Dorothy P. Whelan
`Reg. No. 33,814
`
`
`
`
`
`
`
`Date:May 26, 2020
`
`
`Customer Number 26191
`Fish & Richardson P.C.
`Telephone: (612) 337-2509
`Facsimile: (877) 769-7945
`
`
`
`
`
`
`
`4
`
`
`
`Case PGR2020-00064
`Attorney Docket No: 48751-0005PS1
`
`
`
`CERTIFICATE OF SERVICE
`
`Pursuant to 37 CFR § 42.6(e), the undersigned certifies that on May 26,
`
`2020, a complete and entire copy of this Patent Owner Exela Pharma Sciences,
`
`LLC’s Mandatory Notices and Power of Attorney were provided via email, to the
`
`Petitioner by serving the email correspondence addresses of record as follows:
`
`Ralph J. Gabric
`Eugene Goryunov
`Judy K. He
`Jeff Wolfson
`Haynes and Boone LLP
`2323 Victory Ave., Suite 700
`Dallas, TX 75219
`
`Email: ralph.gabric.ipr@haynesboone.com
`Email: eugene.goryunov.ipr@haynesboone.com
`Email: judy.he.ipr@haynesboone.com
`Email: jeff.wolfson.ipr@haynesboone.com
`
`
`
`
`
`
`
`/Edward G. Faeth/
`Edward G. Faeth
`Fish & Richardson P.C.
`60 South Sixth Street, Suite 3200
`Minneapolis, MN 55402
`(202) 626-6420
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`5
`
`
`
`
`
`
`
`
`
`
`